Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the IDH mutation and 1p/19q co-deletion. Here we present an integrated analysis of the transcriptome, genome and methylome of 156 OT. Not only does our multi-omics classification match the current classification but also reveals three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (OPC) and neuronal lineage. We confirm the validity of these three subgroups using public datasets. Importantly, the OPC-like group is associated with more aggressive clinical and molecular patterns, including MYC activation. We show that the MYC activation occurs through various alterations, including MYC genomic gain, MAX genomic loss, MYC hypomethylation and microRNA-34b/c down-regulation. In the lower grade glioma TCGA dataset, the OPC-like group is associated with a poorer outcome independently of histological grade. Our study reveals previously unrecognized heterogeneity among 1p/19q co-deleted tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Genome-wide atlas of gene expression in the adult mouse brain
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., et al. (2007) · Nature · doi:10.1038/nature05453 · Cited by 5,572
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129 · cited 1×
“3b); O2 tumours strongly over-expressed neuron markers 13,14 and genes implicated in neurogenesis; and O3 tumours specifically expressed mature oligodendrocyte markers 14,15 .”
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236 · cited 2×
“In addition, two negative regulators of MYC , mir34b and mir34c 21–23 , were down-regulated in O1 tumours and their transcription start sites, lying within the mir34b/c CpG island, were hypermethylated in both POLA and TCGA datasets (Supplementary Fig.”
Chen, Y., Wu, H., Wang, S., Koito, H., Li, J., Ye, F., Hoang, J., Escobar, S. S., Gow, A., Arnett, H. A., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2410 · Cited by 346
Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Forest, F., Maurage, C.-A., Vignaud, J.-M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou047 · Cited by 63
Self-citation
Cited by
Integrated omics: tools, advances and future approaches
Misra, B. B., Langefeld, C., Olivier, M., & Cox, L. A. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0055 · Cited by 686
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
Multi-Omics Profiling for Health
Babu, M., & Snyder, M. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100561 · Cited by 406
The Role of Artificial Intelligence in Early Cancer Diagnosis
Hunter, B., Hindocha, S., & Lee, R. W. (2022) · Cancers · doi:10.3390/cancers14061524 · Cited by 332
Metadata
- Authors
- Kamoun, A., Idbaih, A., Dehais, C., Elarouci, N., Carpentier, C., Letouzé, E., Colin, C., Mokhtari, K., Jouvet, A., Uro-Coste, E., Martin-Duverneuil, N., Sanson, M., Delattre, J.-Y., Figarella-Branger, D., de Reyniès, A., Ducray, F., POLA network, Adam, C., Andraud, M., Aubriot-Lorton, M.-H., Bauchet, L., Beauchesne, P., Bielle, F., Blechet, C., Campone, M., Carpentier, A. F., Carpiuc, I., Cazals-Hatem, D., Chenard, M.-P., Chiforeanu, D., Chinot, O., Cohen-Moyal, E., Colin, P., Dam-Hieu, P., Desenclos, C., Desse, N., Dhermain, F., Diebold, M.-D., Eimer, S., Faillot, T., Fesneau, M., Fontaine, D., Gaillard, S., Gauchotte, G., Gaultier, C., Ghiringhelli, F., Godard, J., Gueye, E. M., Guillamo, J. S., Hamdi-Elouadhani, S., Honnorat, J., Kemeny, J. L., Khallil, T., Labrousse, F., Langlois, O., Laquerriere, A., Larrieu-Ciron, D., Lechapt-Zalcman, E., Guérinel, C. L., Levillain, P.-M., Loiseau, H., Loussouarn, D., Maurage, C.-A., Menei, P., Motsuo Fotso, M. J., Noel, G., Parker, F., Peoc'h, M., Polivka, M., Quintin-Roué, I., Ramirez, C., Ricard, D., Richard, P., Rigau, V., Rousseau, A., Runavot, G., Sevestre, H., Tortel, M. C., Vandenbos, F., Vauleon, E., Viennet, G., & Villa, C.
- Venue
- Nature Communications
- Published
- 2016-04-19
- Volume
- 7
- Issue
- 1
- Pages
- 11263-11263
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2336375427
- Cited by
- 104
- References
- 8
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.